ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

LLY Eli Lilly and Co

776.50
-1.68 (-0.22%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Eli Lilly and Co NYSE:LLY NYSE Common Stock
  Price Change % Change Share Price High Price Low Price Open Price Shares Traded Last Trade
  -1.68 -0.22% 776.50 793.67 776.44 780.32 3,209,576 23:59:22

Lilly's Type 2 Diabetes Drug Trulicity Gets FDA OK -- 2nd Update

19/09/2014 12:43am

Dow Jones News


Eli Lilly (NYSE:LLY)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Eli Lilly Charts.
   By Josh Beckerman 
 

Eli Lilly & Co.'s (LLY) Type 2 diabetes drug Trulicity has been approved by the U.S. Food and Drug Administration, the agency said Thursday.

The drug is a subcutaneous injection that helps improve blood-sugar levels.

Lilly plans to launch Trulicity 0.75 mg and 1.5 mg single-dose pens later this year, the company said Thursday. This is the first regulatory approval for the drug, which has been submitted to other regulators including the European Medicines Agency and other regulatory bodies.

The FDA is requiring certain post-marketing studies for Trulicity, including a clinical trial to evaluate effectiveness and safety in pediatric patients.

After the company met with analysts to discuss the drug in June, J.P. Morgan estimated Trulicity would post about $1.4 billion in 2020 sales.

Trulicity, or dulaglutide, belongs to a class of drugs called GLP-1 receptor agonists, which work by stimulating the body's natural production of insulin and help regulate blood-sugar levels.

Lilly said in February that the drug was comparable to Novo Nordisk A/S's (NVO) once-daily Victoza in reducing a measure of blood sugar in a patient study.

Write to Josh Beckerman at josh.beckerman@wsj.com

Access Investor Kit for Eli Lilly & Co.

Visit http://www.companyspotlight.com/partner?cp_code=A591&isin=US5324571083

Subscribe to WSJ: http://online.wsj.com?mod=djnwires


1 Year Eli Lilly Chart

1 Year Eli Lilly Chart

1 Month Eli Lilly Chart

1 Month Eli Lilly Chart

Your Recent History

Delayed Upgrade Clock